It May Be Time to Sell Shares of Integra Lifesciences (NASDAQ:IART) as J.P. Morgan Has Downgraded The Company

January 13, 2018 - By Ellis Scott

  It May Be Time to Sell Shares of Integra Lifesciences (NASDAQ:IART) as J.P. Morgan Has Downgraded The Company

Investors sentiment increased to 1.29 in 2017 Q3. Its up 0.15, from 1.14 in 2017Q2. It increased, as 22 investors sold Integra LifeSciences Holdings Corporation shares while 60 reduced holdings. 26 funds opened positions while 80 raised stakes. 68.21 million shares or 2.93% more from 66.26 million shares in 2017Q2 were reported.

Public Employees Retirement Association Of Colorado reported 12,648 shares. 213,602 are held by Eaton Vance. Laurion Capital Mngmt Limited Partnership stated it has 23,700 shares or 0.01% of all its holdings. X Ltd reported 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Nuveen Asset Ltd Limited Liability Company owns 20,369 shares. 451,309 were reported by Massachusetts Services Com Ma. Huntington Bank & Trust reported 0% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Louisiana State Employees Retirement reported 25,600 shares. First Tru Advsrs L P stated it has 0.01% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Boston Prtn accumulated 371,888 shares. Fifth Third Bancshares holds 0% or 1,652 shares. 55,917 were reported by Employees Retirement Of Ohio. Falcon Point Lc reported 1.73% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Thrivent Fincl For Lutherans has invested 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). New York-based Amer Interest has invested 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Integra Lifesciences (NASDAQ:IART) Receives a Downgrade

J.P. Morgan decreased their rating for shares of Integra Lifesciences (NASDAQ:IART) stock to a solid Hold. This change was sent to investors and clients in a report earlier today. The financial firm from today now has a $44.0 PT on company.

Investors sentiment increased to 1.29 in 2017 Q3. Its up 0.15, from 1.14 in 2017Q2. It increased, as 22 investors sold Integra LifeSciences Holdings Corporation shares while 60 reduced holdings. 26 funds opened positions while 80 raised stakes. 68.21 million shares or 2.93% more from 66.26 million shares in 2017Q2 were reported.

Public Employees Retirement Association Of Colorado reported 12,648 shares. 213,602 are held by Eaton Vance. Laurion Capital Mngmt Limited Partnership stated it has 23,700 shares or 0.01% of all its holdings. X Ltd reported 0% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Nuveen Asset Ltd Limited Liability Company owns 20,369 shares. 451,309 were reported by Massachusetts Services Com Ma. Huntington Bank & Trust reported 0% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Louisiana State Employees Retirement reported 25,600 shares. First Tru Advsrs L P stated it has 0.01% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Boston Prtn accumulated 371,888 shares. Fifth Third Bancshares holds 0% or 1,652 shares. 55,917 were reported by Employees Retirement Of Ohio. Falcon Point Lc reported 1.73% of its portfolio in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Thrivent Fincl For Lutherans has invested 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). New York-based Amer Interest has invested 0.01% in Integra LifeSciences Holdings Corporation (NASDAQ:IART).

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

Among 15 analysts covering Integra Lifesciences Holdings Corp. (NASDAQ:IART), 8 have Buy rating, 0 Sell and 7 Hold. Therefore 53% are positive. Integra Lifesciences Holdings Corp. has $96 highest and $44.0 lowest target. $60.73’s average target is 20.09% above currents $50.57 stock price. Integra Lifesciences Holdings Corp. had 35 analyst reports since July 29, 2015 according to SRatingsIntel. The firm earned “Hold” rating on Friday, September 1 by RBC Capital Markets. The company was downgraded on Friday, October 27 by JP Morgan. On Friday, June 23 the stock rating was maintained by Oppenheimer with “Buy”. The rating was maintained by Jefferies on Tuesday, May 30 with “Buy”. The firm has “Buy” rating by Jefferies given on Tuesday, October 10. The firm has “Equal Weight” rating by Barclays Capital given on Friday, July 29. The rating was maintained by RBC Capital Markets with “Hold” on Wednesday, July 26. The firm earned “Overweight” rating on Wednesday, July 13 by JP Morgan. The rating was maintained by RBC Capital Markets on Friday, January 13 with “Sector Perform”. Raymond James maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) rating on Thursday, July 27. Raymond James has “Outperform” rating and $55 target.

The stock increased 0.20% or $0.1 during the last trading session, reaching $50.57. About 352,799 shares traded. Integra LifeSciences Holdings Corporation (NASDAQ:IART) has risen 32.67% since January 13, 2017 and is uptrending. It has outperformed by 15.97% the S&P500.

Analysts await Integra LifeSciences Holdings Corporation (NASDAQ:IART) to report earnings on February, 22. They expect $0.56 EPS, up 7.69 % or $0.04 from last year’s $0.52 per share. IART’s profit will be $43.95 million for 22.58 P/E if the $0.56 EPS becomes a reality. After $0.45 actual EPS reported by Integra LifeSciences Holdings Corporation for the previous quarter, Wall Street now forecasts 24.44 % EPS growth.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company has market cap of $3.97 billion. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies. It has a 82.77 P/E ratio. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

More notable recent Integra LifeSciences Holdings Corporation (NASDAQ:IART) news were published by: Seekingalpha.com which released: “Integra LifeSciences Holdings’ (IART) CEO Peter Arduini Presents at Morgan …” on September 12, 2017, also Seekingalpha.com with their article: “Integra LifeSciences Holdings’ (IART) CEO Peter Arduini on Q3 2017 Results …” published on October 26, 2017, Globenewswire.com published: “Integra LifeSciences to Host Third Quarter 2017 Earnings Results Conference …” on October 11, 2017. More interesting news about Integra LifeSciences Holdings Corporation (NASDAQ:IART) were released by: Globenewswire.com and their article: “Integra LifeSciences launches Revizeâ„¢/ Revizeâ„¢-X Collagen Matrix for Plastic …” published on October 06, 2017 as well as Nasdaq.com‘s news article titled: “Integra LifeSciences Estimates Strong Revenue Figures for Q4” with publication date: January 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.